Related Experiment Video
Updated: Jan 30, 2026

Studying Aggression in Drosophila fruit flies
Published on: February 25, 2007
Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis
Vanessa M López-Ozuna1, Ibrahim Y Hachim1, Mahmood Y Hachim2
1Department of Medicine, Cancer Research Program, McGill University Health Centre, McGill University, Montreal, Québec, Canada.
Abstract:
Triple-negative breast cancer (TNBC) accounts for ~20% of all breast cancer cases. The management of TNBC represents a challenge due to its aggressive phenotype, heterogeneity and lack of targeted therapy. Loss of cell differentiation and enrichment with breast cancer stem-like cells (BCSC) are features of TNBC contributing to its aggressive nature. Here, we found that treatment of TNBC cells with PRL significantly depletes the highly tumorigenic BCSC subpopulations CD44+/CD24- and ALDH+ and differentiates them to the least tumorigenic CD44-/CD24- and ALDH- phenotype with limited tumorsphere formation and self-renewal capacities. Importantly, we found PRL to induce a heterochromatin phenotype marked by histone H3 lysine 9 trimethylation (H3K9me3) and accompanied by ultra-structural cellular architecture associated with differentiation and senescence rendering the cells refractory to growth signals. Crucially, we found PRL to mediate these effects in vivo in a pre-clinical animal xenograft of TNBC controlling tumor growth. These results reveal that the lactogenic hormone PRL may exert its anti-tumorigenic effects on TNBC through cellular reprogramming indicative of differentiation resulting in the depletion of BCSCs and restricting tumorigenesis.
Insights
The lactogenic hormone prolactin (PRL) depletes aggressive breast cancer stem cells in triple-negative breast cancer (TNBC). This reprogramming induces differentiation, reduces tumor growth, and offers a potential new therapeutic strategy for TNBC.
Area of Science:
- Oncology
- Cell Biology
- Endocrinology
Background:
- Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies.
- TNBC is characterized by poor differentiation and enrichment of cancer stem-like cells (CSCs).
- Breast cancer stem-like cells (BCSCs) drive tumor aggressiveness and recurrence.
Purpose of the Study:
- To investigate the effect of prolactin (PRL) on BCSCs in TNBC.
- To explore PRL's potential as a therapeutic agent for TNBC.
Main Methods:
- Treatment of TNBC cells with PRL.
- Analysis of BCSC subpopulations (CD44+/CD24-, ALDH+).
- Assessment of tumorsphere formation and self-renewal capacity.
- Histological and molecular analysis of cellular differentiation and senescence (H3K9me3).
- In vivo evaluation in a TNBC xenograft mouse model.
Main Results:
- PRL treatment significantly depleted CD44+/CD24- and ALDH+ BCSCs.
- PRL induced differentiation towards a less tumorigenic phenotype (CD44-/CD24-, ALDH-).
- PRL treatment limited tumorsphere formation and self-renewal capacity.
- PRL induced a heterochromatin phenotype (H3K9me3) associated with differentiation and senescence.
- PRL controlled tumor growth in a pre-clinical TNBC xenograft model.
Conclusions:
- PRL exerts anti-tumorigenic effects on TNBC by depleting BCSCs.
- PRL promotes cellular reprogramming and differentiation in TNBC cells.
- PRL's effects on BCSCs and tumor growth suggest potential therapeutic applications for TNBC.
Related Concept Videos
Aggression
Limiting Reactant
The Number e as a Limit
Types of Limits I
Limit Laws I
Introduction to Limits

